Impact of DNA damage response defects in cancer cells on response to immunotherapy and radiotherapy

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• The DNA damage response (DDR) is crucial for maintaining genomic stability.
• Tumors often have inactivated DDR components, leading to DNA defects and potential therapeutic targets.
• DDR inhibition can sensitize cancers to radiotherapy and predict response to immune checkpoint inhibition.

Purpose of the Study:

• To explore the therapeutic potential of targeting the DNA damage response (DDR) in cancer treatment.
• To investigate how DDR inhibition can enhance the efficacy of radiotherapy and immunotherapy.
• To understand the role of DDR defects in predicting patient response to immune checkpoint inhibition.

Main Methods:

• Review of existing literature on DDR pathways and their role in cancer.
• Analysis of preclinical and clinical data on DDR inhibitors.
• Exploration of combinatorial strategies involving DDR inhibition, radiotherapy, and immunotherapy.

Main Results:

• Inhibition of DDR can induce radiosensitivity in specific cancer types.
• DDR defects are significant predictors of patient response to immune checkpoint inhibition (ICI).
• Targeting DDR can increase tumor immunogenicity by expanding neoantigens, promoting anti-tumor immune responses.

Conclusions:

• Targeting the DNA damage response (DDR) presents a promising strategy for cancer therapy.
• Combinatorial approaches integrating DDR inhibition with radiotherapy and immunotherapy show potential.
• Further research is needed to elucidate DDR synergies and develop reliable biomarkers for patient selection.